Dr Jane Meisel comments on Dr Hope Hugo's study on the use of sacituzumab govitecan (trodelvy) an antibody-drug conjugate which resulted in longer progression-free survival compared to the physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer.

Dr Meisel discusses the significance of the study for estrogen positive endocrine resistant patients stating that this has previously been an area of great unmet need. 

Reflecting on the results of the study, she concludes that sacituzumab govitecan tends to work better than chemotherapy when compared, then goes onto highlight the study as 'a step forward for the field.'

Read the article here

Watch the press conference here

Watch the interview here